Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

In 2011, AstraZeneca embarked on a major revision of its research and development (R&D)
strategy with the aim of improving R&D productivity, which was below industry averages in …

Summary Background The Xpert MTB/RIF assay is an automated molecular test that has
improved the detection of tuberculosis and rifampicin resistance, but its sensitivity is …

ABSTRACT The Xpert MTB/RIF assay (Xpert) is a rapid test for tuberculosis (TB) and
rifampin resistance (RIF-R) suitable for point-of-care testing. However, it has decreased …

Background Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert Ultra), the
newest version, are the only World Health Organization (WHO)‐recommended rapid tests …

Tuberculosis (TB) is a major cause of morbidity and mortality worldwide. It is estimated that
25% of the world's population are infected with Mycobacterium tuberculosis, with a 5–10 …

Study Design: Review article. Objectives: A review of literature on the epidemiology,
diagnosis, and management of spinal tuberculosis (TB). Methods: A systematic …

Antimicrobial susceptibility testing (AST) technologies help to accelerate the initiation of
targeted antimicrobial therapy for patients with infections and could potentially extend the …

Background Community-based active case-finding interventions might identify and treat
more people with tuberculosis disease than standard case detection. We aimed to assess …

Background Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over …